Epidemiology Articles

Gain free access to the latest articles on the NASH and NAFLD epidemic by a global expert community. ⌨

Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Authors: Fromenty B, Roden M
Published in Journal of Hepatology (February 2023)
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Read MoreExamining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Insights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?

Authors: Chew NWS, Ng CH, Tan DJH et al.
Published in Cell Metabolism (March 2023)
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver disease (NAFLD), accounts for a significant proportion of this burden.
Read MoreInsights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?

NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?

Authors: Sanyal AJ, Magnanensi J, Majd Z et al.
Published in Hepatology Communications (September 2023)
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
Read MoreNIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?

Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?

Authors: Bouriser J, Canivet CM, Costentin C et al.
Published in Clinical Gastroenterology and Hepatology (May 2023)
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Read MoreAre Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?

Exploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD

Authors: Slusher AL, Hu P, Samuels S et al.
Published in Pediatric Obesity (December 2022)
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease in children, has seen a consistent rise in prevalence in recent years due to its direct link with obesity and type 2 diabetes (T2D).
Read MoreExploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD

“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Authors: Francque SM, Noureddin M, Krag A
Published in Clinical Gastroenterology and Hepatology (August 2023)
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Read More“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Understanding Nash: Symptoms, Detection, And Treatment

Authors: Basu M, Noureddin M, Clark JM
Published in Mayo Clinic Proceedings (September 2022)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Read MoreUnderstanding Nash: Symptoms, Detection, And Treatment

An exploration of MAFLD’s clinical utility

Authors: Ramírez-Mejía MM, Xingshun Q, Abenavoli L et al
Published in Annals of Hepatology (July 2023)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utility

NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Authors: Loomba R, Huang DQ, Sanyal AJ et al.
Published in Gut (March 2023)
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

Authors: Younossi ZM, Golabi P, Paik JM et al.
Published in Hepatology (April 2023)
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Read MoreNAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES